Peak6 LLC Takes $251,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Peak6 LLC bought a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 3,000 shares of the biopharmaceutical company’s stock, valued at approximately $251,000.

A number of other large investors have also added to or reduced their stakes in the business. GAMMA Investing LLC increased its holdings in shares of Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 240 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth about $96,000. Wilmington Savings Fund Society FSB acquired a new position in Intra-Cellular Therapies in the 3rd quarter valued at about $97,000. Covestor Ltd raised its holdings in Intra-Cellular Therapies by 15.9% in the 4th quarter. Covestor Ltd now owns 2,099 shares of the biopharmaceutical company’s stock valued at $175,000 after acquiring an additional 288 shares during the period. Finally, Barlow Wealth Partners Inc. acquired a new stake in Intra-Cellular Therapies during the fourth quarter worth approximately $184,000. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

Intra-Cellular Therapies stock opened at $131.87 on Tuesday. The stock has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 12-month low of $64.09 and a 12-month high of $131.98. The business’s 50-day moving average price is $130.84 and its two-hundred day moving average price is $106.85.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ITCI shares. Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. StockNews.com started coverage on Intra-Cellular Therapies in a research report on Monday. They set a “hold” rating on the stock. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Finally, Baird R W cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Eleven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Intra-Cellular Therapies presently has a consensus rating of “Hold” and a consensus target price of $109.70.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.